Pharming Group is a Dutch biopharmaceutical company specializing in rare diseases, notably hereditary angioedema and primary immunodeficiencies. It commercializes therapies such as Ruconest, a recombinant C1 esterase inhibitor for acute HAE attacks, and has expanded into additional rare immunology indications. Customers are mainly specialist physicians and patients in ultra-orphan markets where few alternatives exist.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 93.2 | — | 4.7 | — |
| Q3 2025 | 97.3 | — | 7.5 | — |
| Q4 2025 | 106.5 | — | 5.3 | — |
| Q1 2026 | 72.5 | — | -5.2 | — |
| Q2 2026 | 90.2 | -3.2% | 1.6 | -65.1% |
All markets — KeepWinning global stock screener
Other companies on Euronext Amsterdam: Nedap N.V. (NEDAP), TomTom N.V. (TOM2), ForFarmers N.V. (FFARM), ASML Holding N.V. (ASML), Shell plc (SHELL), Unilever PLC (UNA)